Key Performance
More- Earnings Score: 21
- Momentum Score: 65
- True Yield: N/A
- Financial Health Score: 96
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
Prosight Management increased its stake in Nektar Therapeutics by 180,367 shares ($10.27 million) in Q1 2026, making it the fund's largest position at 8.67% of AUM. The biotech company's stock has surged nearly 600% over the past year as it prepares to launch Phase 3 trials for rezpegaldesleukin, its experimental autoimmune disease treatment. With over $1 billion in liquidity, Nektar is well-positioned financially, though success depends on late-stage clinical trial outcomes.
05/23/2026, 4:28 PM • The Motley Fool
A class action lawsuit has been filed against Nektar Therapeutics alleging that company defendants made materially false and misleading statements regarding the REZOLVE-AA trial. The complaint claims that enrollment in the trial did not follow applicable protocol standards, which likely had a significant negative impact on trial results and overall integrity. Investors who purchased Nektar securities between February 26, 2025 and December 25, 2025 are encouraged to join the case.
05/05/2026, 12:00 PM • GlobeNewswire
Nektar Therapeutics faces a securities class action lawsuit alleging the company misrepresented enrollment standards in its REZOLVE-AA Phase 2b clinical trial. Four patients with major eligibility violations were included in the trial, including two with unstable alopecia areata diagnosed less than six months prior and two who began treatment before completing the required eight-week medication washout period. The trial's primary endpoint missed statistical significance with these ineligible patients included but met significance when they were excluded. The company had made repeated assurances about rigorous enrollment protocols across press releases, earnings calls, and SEC filings from February through November 2025. The lead plaintiff deadline is May 5, 2026.
05/04/2026, 8:23 PM • GlobeNewswire
A class action lawsuit has been filed against Nektar Therapeutics for allegedly making false statements about its REZOLVE-AA trial. The company failed to disclose that trial enrollment did not follow protocol standards, and four ineligible patients were included. When Nektar announced the trial's failure to reach statistical significance on December 16, 2025, its stock fell 7.77%. Investors who purchased shares between February 26, 2025 and December 15, 2025 can join the lawsuit by May 5, 2026.
05/04/2026, 6:57 PM • GlobeNewswire
A securities class action lawsuit has been filed against Nektar Therapeutics for allegedly making false and misleading statements regarding the REZOLVE-AA trial. The lawsuit claims the company failed to disclose that enrollment in the trial did not follow applicable instructions and protocol standards, which negatively impacted trial results and integrity. Investors who purchased NKTR securities between February 26, 2025 and December 15, 2025 may be eligible for compensation. The lead plaintiff deadline is May 5, 2026.
05/03/2026, 9:38 PM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits against Regencell Bioscience Holdings Limited, Globant S.A., and Nektar Therapeutics on behalf of investors who purchased securities during specified periods. The lawsuits allege that defendants made false and/or misleading statements regarding market manipulation vulnerabilities, regulatory risks, and financial exposure. Investors have until June 23, 2026 to move the court to serve as lead plaintiff.
05/03/2026, 9:30 PM • GlobeNewswire
A class action lawsuit has been filed against Nektar Therapeutics alleging that the company made materially false and misleading statements regarding its REZOLVE-AA trial. The complaint claims that enrollment in the trial did not follow applicable protocol standards, which likely had a significant negative impact on trial results and overall integrity. Investors who purchased Nektar securities between February 26, 2025 and December 25, 2025 are encouraged to join the case.
05/01/2026, 12:00 PM • GlobeNewswire
A class action lawsuit has been filed against Nektar Therapeutics alleging that company defendants made materially false and misleading statements regarding the REZOLVE-AA trial. The complaint claims enrollment in the trial did not follow applicable protocol standards, which likely negatively impacted trial results and overstated the trial's integrity and prospects. Investors who purchased Nektar securities between February 26, 2025 and December 25, 2025 are encouraged to join the case, with a lead plaintiff deadline of May 5, 2026.
04/28/2026, 12:00 PM • GlobeNewswire
Nektar Therapeutics faces a securities fraud class action lawsuit after its Phase 2b REZOLVE-AA trial for alopecia areata treatment failed to reach statistical significance. The company allegedly failed to disclose that trial enrollment did not follow protocol standards, leading to a 7.8% stock price decline on December 16, 2025. Investors have until May 5, 2026 to file a lead plaintiff motion.
04/24/2026, 12:59 PM • GlobeNewswire
A class action lawsuit has been filed against Nektar Therapeutics alleging that the company made materially false and misleading statements regarding its REZOLVE-AA trial. The complaint claims that enrollment in the trial did not follow applicable protocol standards, which likely had a significant negative impact on trial results and overall integrity. Investors who purchased Nektar securities between February 26, 2025 and December 25, 2025 are encouraged to join the case, with a lead plaintiff deadline of May 5, 2026.
04/24/2026, 12:00 PM • GlobeNewswire
Rosen Law Firm is notifying investors who purchased Nektar Therapeutics securities between February 26, 2025 and December 15, 2025 about a securities class action lawsuit. The lawsuit alleges that Nektar made false and misleading statements regarding enrollment protocols in the REZOLVE-AA trial, which allegedly overstated the trial's integrity and prospects. Investors have until May 5, 2026 to serve as lead plaintiff.
04/21/2026, 8:39 PM • GlobeNewswire
Pomerantz Law Firm has filed class action lawsuits against Aquestive Therapeutics, Eos Energy Enterprises, and Nektar Therapeutics, alleging securities fraud and unlawful business practices. The lawsuit against Aquestive was triggered by an FDA letter identifying deficiencies in the Anaphylm NDA review, causing the stock to drop 37% on January 9, 2026. Investors have until May 4, 2026, to request Lead Plaintiff status.
04/21/2026, 3:59 PM • GlobeNewswire
Pomerantz LLP filed a class action lawsuit against Nektar Therapeutics for alleged securities fraud related to its REZOLVE-AA clinical trial. The lawsuit claims Nektar made false statements about trial enrollment compliance and integrity. In December 2025, Nektar announced the trial failed to reach statistical significance due to four ineligible patients being included, causing the stock to drop 7.77%.
04/21/2026, 3:59 PM • GlobeNewswire
Pomerantz Law Firm has filed class action lawsuits against Eos Energy Enterprises, Nektar Therapeutics, and Aquestive Therapeutics for alleged securities fraud. Eos Energy's stock fell 39.44% after missing earnings estimates significantly, with the company citing production issues and quality control problems.
04/21/2026, 3:59 PM • GlobeNewswire
Pomerantz Law Firm has filed class action lawsuits against Corcept Therapeutics, Eos Energy Enterprises, and Nektar Therapeutics. The primary case involves Corcept, which faced a 50.4% stock price decline after the FDA issued a Complete Response Letter for its relacorilant drug, citing insufficient evidence of effectiveness. Investors with losses are urged to contact the firm by the April 21, 2026 deadline to potentially serve as lead plaintiff.
04/21/2026, 3:56 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.